Opioid Use Disorder Treatment Market - Strategic Insights and Forecasts (2026-2031)

The opioid use disorder treatment market, at a 7.25% CAGR, is anticipated to reach USD 11.55 billion in 2031 from USD 7.59 billion in 2025.

The demand for Opioid Use Disorder (OUD) treatment is currently undergoing a massive recalibration as public health departments prioritize evidence-based stabilization over abstinence-only models. This shift originates from the increasing lethality of synthetic opioids, which forces healthcare systems to adopt high-affinity partial agonists like buprenorphine as a first-line survival mechanism. Dependency on this market is expanding as the 2024 SAMHSA Final Rule (42 CFR Part 8) permanently integrates telehealth flexibilities, allowing patients to initiate and maintain treatment without the logistical constraints of daily clinic attendance. Regulatory influence acts as a primary catalyst, as government-mandated "take-home" dose expansions and the elimination of the "X-waiver" in the United States are removing previous bottlenecks in prescriber capacity. Strategically, the market serves as a critical infrastructure layer for national security and economic stability, as governments utilize opioid settlement funds to subsidize long-term treatment nodes and reduce the broader social costs of the overdose epidemic.

Market Dynamics

Drivers

• Shift in Clinical Guidelines: Global healthcare protocols are increasingly prioritizing Medications for Opioid Use Disorder (MOUD) as the "gold standard" for reducing all-cause mortality. This structural change is driving insurance providers to expand coverage for buprenorphine-based therapies, which reduces out-of-pocket costs for patients and incentivizes long-term adherence.

• Long-Acting Buprenorphine Adoption: Demand is transitioning toward extended-release formulations like Sublocade and Brixadi. This shift occurs because monthly injections remove the daily burden of pill or film administration, leading to stabilized plasma levels and improved psychological outcomes for patients in early recovery.

• Liberalization of Methadone Access: The 2024 federal updates to 42 CFR Part 8 are allowing Opioid Treatment Programs (OTPs) to offer expanded take-home supplies much earlier in the treatment cycle. This policy change is reducing the travel-related barriers that previously forced many patients to discontinue treatment, thereby sustaining higher longitudinal demand for methadone syrup and tablets.

• Government Settlement Payouts: Massive financial settlements from opioid-related litigation are reaching state and local health departments in 2025 and 2026. These funds are specifically flowing into the expansion of treatment infrastructure, which increases the total capacity of specialized clinics and rehabilitation centers to handle higher patient throughput.

Restraints and Opportunities

• Persistent Social Stigma: Cultural biases against medication-assisted treatment continue to restrict the adoption of OUD pharmaceuticals in certain conservative regions. This stigma discourages patients from seeking help and limits the willingness of primary care physicians to integrate OUD management into their practices, though educational campaigns are slowly mitigating these effects.

• Supply Chain Vulnerabilities: The manufacturing of controlled substances remains subject to strict DEA production quotas and specialized distribution requirements. These regulatory constraints are creating localized shortages of generic buprenorphine/naloxone films, forcing providers to switch patients to more expensive branded alternatives or less convenient dosing forms.

• Opportunity in Digital Therapeutics: The integration of FDA-cleared digital therapeutics with pharmacological treatment is creating a new market for hybrid care. Software platforms are providing real-time behavioral monitoring and cognitive behavioral therapy (CBT) modules that complement medications, offering a pathway for pharmaceutical companies to enhance the efficacy of their existing drug portfolios.

• Expansion of Prison-Based Treatment: Correctional facilities are increasingly implementing OUD treatment programs as part of recidivism reduction strategies. This emerging end-user segment is creating a surge in demand for non-divertible injectable treatments, as prison healthcare systems seek to stabilize incarcerated individuals prior to their release.

Supply Chain Analysis

The supply chain for OUD treatment is governed by a high-security framework that manages the flow from Active Pharmaceutical Ingredient (API) production to point-of-care dispensing. API manufacturers operate under stringent international narcotics controls, which ensures that precursors for methadone and buprenorphine remain tracked and accounted for throughout the synthesis process. Once formulated, these medications move through specialized wholesalers that maintain Class II or Class III vault storage to prevent theft and diversion.

Demand is currently forcing a reconfiguration of the downstream supply chain as retail pharmacies and Opioid Treatment Programs (OTPs) adapt to new "take-home" regulations. The 2024 SAMHSA rule change is increasing the volume of medication moving through community pharmacy channels, as more patients receive multi-week prescriptions rather than single-day clinic doses. This shift is placing pressure on regional distributors to increase delivery frequency for buprenorphine products. Simultaneously, manufacturers are investing in cold-chain logistics for long-acting injectables, which require temperature-controlled environments to maintain molecular stability. This infrastructure expansion is critical for supporting the growth of specialized clinics that lack extensive on-site pharmaceutical storage capacity.

Government Regulations

Key Developments

• March 2026: Braeburn announced landmark clinical results for BRIXADI, proving its efficacy for pregnant and postpartum women. This evidence-based milestone officially expands the reach of this long-acting injectable in a critical sub-market.

• February 2026: Alkermes completed its acquisition of Avadel Pharmaceuticals. This strategic move diversifies its neuroscience portfolio and strengthens its commercial infrastructure, directly supporting the long-term growth of its OUD franchise.

Market Segmentation

By Treatment Type

Demand within the OUD treatment sector is fundamentally dictated by the pharmacological profile and regulatory status of the specific medication being utilized. Medication-assisted treatment (MAT) serves as the primary anchor, as clinical evidence consistently proves its superiority in preventing relapse compared to behavioral therapy alone. Within this segment, Buprenorphine is capturing a significant portion of the market because its partial-agonist properties allow for safer home-based administration with a lower risk of overdose. Patients are increasingly opting for buprenorphine-naloxone combinations, which include abuse-deterrent features, effectively reducing the potential for injection of oral products.

Conversely, Methadone remains a structural staple for patients requiring a full agonist to manage severe withdrawal and high tolerance levels. While methadone still requires highly regulated dispensing through authorized Opioid Treatment Programs (OTPs), the 2024 regulatory changes are making this medication more accessible via expanded take-home privileges. This transition is reducing the daily "liquid line" burden, which is encouraging more long-term users to remain in treatment. Naltrexone, an antagonist that requires full detoxification before initiation, is seeing steady demand within the criminal justice system and for patients who are highly motivated to achieve a complete opioid-free status. The market for Counseling and Behavioral Therapies is evolving into a supportive service that is often integrated into digital platforms, as healthcare providers recognize that psychological support is essential for improving the longevity of pharmacological outcomes.

By Route of Administration

The market is currently witnessing a decisive structural shift from Oral to Injectable routes of administration. Oral medications, including sublingual films and tablets, represent the historical baseline of treatment. However, demand for these products is facing pressure from the inherent risks of patient non-compliance and accidental pediatric exposure. Enterprises are responding by developing more robust packaging and flavoring, yet the oral segment is losing ground to more reliable delivery systems.

Injectable formulations, specifically long-acting injectables (LAIs), are transforming the market by offering monthly or weekly dosing schedules. These products are being widely adopted by specialized clinics because they remove the possibility of patients selling or "diverting" their medication on the street. Healthcare systems are increasingly favoring injectables as they provide a verified, provider-administered dose that guarantees therapeutic plasma levels for the entire month. This transition is forcing manufacturers to invest in subcutaneous delivery technologies that minimize injection-site reactions and improve patient comfort. As a result, the injectable segment is becoming the primary driver of market value, even as oral formulations continue to provide a necessary low-cost entry point for many patients.

By End-User

The landscape of OUD care is diversifying as the treatment of addiction moves out of the shadows and into mainstream medicine. Specialized Clinics and Opioid Treatment Programs (OTPs) remain the primary hubs for methadone dispensing and intensive patient monitoring. These facilities are currently expanding their services to include integrated primary care and mental health screenings, responding to the need for "whole-person" recovery models. Rehabilitation Centers are also adapting their business models, shifting away from short-term "detox-only" services toward long-term stabilization using MAT. This change is being driven by insurance reimbursement policies that now favor evidence-based treatments over high-cost, short-duration residential programs.

The "Others" segment, which includes hospital pharmacies and correctional facilities, is emerging as a critical growth area. Hospitals are increasingly initiating buprenorphine treatment in the emergency department (ED) after an overdose reversal, which creates a critical bridge to long-term care. Simultaneously, the justice system is becoming a major purchaser of OUD medications as state and federal laws mandate that incarcerated individuals receive access to lifesaving treatments. This expansion into non-traditional settings is broadening the market's reach and ensuring that treatment is available at every point of contact within the healthcare and legal systems.

Regional Analysis

North America

North America dominates the global OUD treatment market as the United States and Canada continue to battle an unprecedented overdose crisis fueled by illicit fentanyl. In the USA, demand is being fundamentally reshaped by federal policy shifts, such as the 2023 elimination of the X-waiver, which is allowing hundreds of thousands of new physicians to prescribe buprenorphine. This massive expansion in prescriber capacity is being supported by federal SOR grants distributed in late 2025, which are actively funding the procurement of medications in underserved rural areas. Furthermore, the US market is seeing the highest adoption rates of long-acting injectables like Sublocade, as private and public payers recognize the cost-savings associated with reduced relapse and emergency room visits.

In Canada, the focus is shifting toward "safer supply" programs and pharmaceutical-grade alternatives to the toxic street supply. Health Canada is approving new high-dose formulations of buprenorphine to counteract the extreme potency of modern synthetic opioids. The provincial healthcare systems in British Columbia and Ontario are leading this transition, integrating OUD treatment into community health centers to reduce the stigma associated with specialized addiction clinics. Mexico is also beginning to see an increase in demand for OUD treatment in its northern border cities, where the local consumption of heroin and synthetics is rising, though access to MAT remains significantly more restricted compared to its northern neighbors.

Europe

The European market is characterized by a strong emphasis on public health and harm reduction, with countries like Germany and France providing wide access to buprenorphine through the general healthcare system. In Germany, the regulatory framework allows for a decentralized model where general practitioners can manage OUD patients, which sustains a high and steady demand for sublingual and injectable medications. France continues to be a leader in buprenorphine adoption, with a significant majority of its OUD population receiving treatment through community pharmacies rather than specialized centers.

In the United Kingdom, the market is recovering from a 2025 transition in distribution models for long-acting injectables like Buvidal. The NHS is increasingly moving toward injectable formulations to manage high-risk populations, specifically those with a history of non-compliance in traditional daily-dose programs. Across the rest of Europe, the European Medicines Agency (EMA) is promoting standardized clinical guidelines that emphasize the use of MAT as an essential health service. This top-down pressure is forcing many Eastern European countries to expand their treatment infrastructure, creating new opportunities for manufacturers of generic buprenorphine and methadone.

Asia Pacific

The Asia Pacific region is entering a phase of rapid market expansion as countries like China and India acknowledge the growing public health threat of opioid dependency. In China, the government is expanding its network of methadone clinics while also exploring the introduction of buprenorphine to provide a more flexible treatment option for its urban workforce. India is seeing a surge in demand for OUD medications as the government’s National Action Plan for Drug Demand Reduction (NAPDDR) increases funding for addiction treatment centers. Local manufacturers in India are also playing a critical role in the global supply chain, producing low-cost generic buprenorphine for both domestic use and export to other developing markets.

Australia remains a highly sophisticated market for OUD treatment, with one of the highest per-capita adoption rates of long-acting injectables in the world. The Australian government’s Pharmaceutical Benefits Scheme (PBS) provides heavy subsidies for these products, making them highly accessible to the general population. This supportive reimbursement environment is encouraging pharmaceutical companies to use Australia as a primary launchpad for new delivery technologies and digital health integrations.

List of Companies

• Indivior Plc

• Alkermes Plc

• Orexo AB

• Titan Pharmaceuticals Inc.

• Teva Pharmaceutical Industries Ltd.

• Mallinckrodt Pharmaceuticals

• Pfizer Inc.

• Hikma Pharmaceuticals PLC

• Camurus

• Collegium Pharmaceuticals

Company Profiles

• Indivior Plc

Indivior is strategically distinct due to its absolute focus on the buprenorphine molecule and its pioneering role in the development of long-acting injectable technology. The company’s flagship product, Sublocade, utilizes a proprietary Atrix drug delivery system that forms a solid depot upon injection, providing a sustained release of buprenorphine over 30 days. This technological advantage allows Indivior to position itself as the market leader in "diversion-free" treatment. The company is currently executing an "Action Agenda" that prioritizes the transition of patients from its older sublingual film, Suboxone, to the more clinical-grade injectable format. By 2026, Indivior is aggressively expanding its presence in the justice system and organized healthcare settings, leveraging its extensive clinical data to prove the long-term cost-effectiveness of its high-value therapeutics.

• Alkermes Plc

Alkermes distinguishes itself through its expertise in complex pharmaceutical chemistry and its commitment to non-addictive antagonist therapies. Its primary product, Vivitrol, is a monthly injectable formulation of naltrexone that blocks opioid receptors without being an opioid itself. This makes Alkermes the preferred partner for "drug-free" treatment programs, particularly within the US criminal justice system and for employers with strict zero-tolerance policies. Strategically, the company is diversifying into other central nervous system (CNS) disorders, which allows it to maintain a broad R&D infrastructure while continuing to optimize its long-acting delivery technologies for the OUD market.

• Camurus

Camurus is strategically distinct for its highly versatile FluidCrystal® technology, which enables the formulation of low-volume, long-acting injectables that do not require refrigeration. Its product, Buvidal (marketed as Brixadi in the US), offers both weekly and monthly dosing options, providing a level of clinical flexibility that its competitors lack. This "dosing agility" allows healthcare providers to tailor treatment to the specific needs of the patient, which is particularly useful during the early, unstable phases of recovery. Camurus is currently leveraging its 2026 revenue growth to expand into Wave 1 markets and is positioning its pipeline to address a broader range of substance use and endocrine disorders.

Analyst View

The OUD treatment market is entering a period of permanent structural expansion as regulatory barriers fall and long-acting injectables become the clinical standard. Stability in this sector is now guaranteed by long-term government funding and settlement-driven infrastructure growth.

Opioid Use Disorder Treatment Market Scope: